Markets:

Overview

News

Currencies

International

Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

60.15 +1.22 (+2.07%)

Streaming Delayed Price Updated: 10:45 AM EST, Feb 17, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

38 39 Next >

3 Bill Gates Stocks to Buy for Billionaire-Like Returns ↗

October 27, 2023

Microsoft and Berkshire Hathaway are the two most popular Bill Gates stocks. Investors know these three others far less.

Via InvestorPlace

3 Deeply Undervalued Growth Stocks ↗

October 27, 2023

As in 2022, the current downturn of stocks appears to be way overdone, making this a good time to buy undervalued growth stocks.

Via InvestorPlace

Peering Into GSK's Recent Short Interest ↗

October 26, 2023

Via Benzinga

Price Over Earnings Overview: GSK ↗

October 24, 2023

Via Benzinga

Bank Of America, Mastercard, NRA And Others Are Lobbying For Cannabis Banking Reform — Who Knew? ↗

October 22, 2023

Several entities have included the Secure and Fair Enforcement Regulation (SAFER) Banking Act on their lobbying disclosures for the third quarter of 2023.

Via Benzinga

Topics Cannabis

Week In Review: Two China Biopharmas Announce Billion Dollar Deals ↗

October 14, 2023

MediLink Therapeutics out-licensed global rights for its antibody-drug conjugate candidate to BioNTech in a $1.1 billion agreement. Meanwhile, BioMap formed a collaboration with Sanofi in a deal with...

Via Talk Markets

(GSK) - Analyzing GSK's Short Interest ↗

October 09, 2023

Via Benzinga

Price Over Earnings Overview: GSK ↗

September 22, 2023

Via Benzinga

GSK: Pharma Giant Prioritizing Shareholder Dividends ↗

October 13, 2023

A good hunting ground for dividend stocks is often companies from which Wall Street wants to see strong performance in the short-term, while its long-term prospects are actually what are most bright.

Via Talk Markets

Google AI-Powered Chatbot's Ethical Concerns, MGM Hackers Waited For Days Before Issuing Financial Demands, Costco Accused Of Sharing Confidential Health Data With Facebook: Today's Top Stories ↗

October 11, 2023

Bloomberg Google's AI Dilemma - Bard's Promise Versus Ethical Concerns

Via Benzinga

Topics Artificial Intelligence Hacking

Little Less Heartburn For GSK: Settles Another California Lawsuit On Zantac ↗

October 11, 2023

GSK plc (NYSE: GSK) has reached a confidential settlement in the Cantlay/Harper case filed in California state court.

Via Benzinga

Topics Lawsuit

China-Based Zhifei Biological Partners With GSK To Expand Shingrix Vaccine Access Across China Via £2.5B Deal ↗

October 09, 2023

GSK plc (NYSE: GSK) has reached an exclus

Via Benzinga

How Is The Market Feeling About GSK? ↗

September 19, 2023

Via Benzinga

Regulatory Shadow Over Saudi Golf League LIV And PGA Tour Merger, Novo Nordisk's Weight Loss Drugs May Pose Serious Stomach Risks, Netflix's Local Content and Pricing Woes Undermine Growth in India: Today's Top Stories ↗

October 06, 2023

Bloomberg Regulatory Shadow Over Saudi Golf League LIV And PGA Tour Merger

Via Benzinga

GSK Cuts Stake In Consumer Healthcare Business Haleon, Raises Around $1B ↗

October 06, 2023

GSK Plc (NYSE: GSK) said it raised £885.6 million (

Via Benzinga

AstraZeneca Settles Heartburn Treatment Lawsuit For One Of Biggest Selling Drug ↗

October 03, 2023

AstraZeneca Plc (NASDAQ: AZN) has

Via Benzinga

Topics Lawsuit

Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant ↗

October 02, 2023

Read the latest report on NanoViricides here

Via Benzinga

7 ‘Smart Money’ Stocks Set to Explode Higher ↗

September 30, 2023

Invest like the pros by wagering on these top seven smart money stocks to buy at this time, offering tremendous upside ahead.

Via InvestorPlace

Moderna's Shares Could Take Off if These 2 Things Happen ↗

September 30, 2023

Moderna stock soared early in the pandemic.

Via The Motley Fool

Biden's Urgent Action Against Antibiotic-Resistant Bacteria - Allocates $100M to Battle Deadly Superbugs ↗

September 27, 2023

U.S. President Joe Biden is set to unveil a $100 million research initiative to tackle the growing threat of drug-resistant bacteria. More than a million people worldwide succumb to infections caused...

Via Benzinga

Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant ↗

September 26, 2023

Read the latest report on NanoViricides here

Via Benzinga

Why Are Antifungal Focused Scynexis Stock Plunging Today? ↗

September 25, 2023

Scynexis Inc (NASDAQ: SCYX) is voluntarily recalling its antifunga

Via Benzinga

CDC Backs Pfizer's RSV Infection Maternal Vaccine During Pregnancy As Protection For Infants ↗

September 25, 2023

Friday, The Centers for Disease Control and Prevention recommended the first respiratory syncytial virus (RSV) vaccine for pregnant people to protect their newborns from severe RSV

Via Benzinga

Amazon Poaches Microsoft's Product Chief, Google And DoD Team Up For AI-Powered Microscope To Identify Cancer, Rocket Lab's 41st Mission Succumbed To Technical Issues: Today's Top Stories ↗

September 19, 2023

Bloomberg

Via Benzinga

European Commission Approves GSK/Pfizer-Backed HIV Infection Prevention Drug ↗

September 19, 2023

The European Commission has approved ViiV Healthcare's Apretude (cabotegravir long-acting (LA) injectable and tablets)

Via Benzinga

Anemia Advantage For GSK's Blood Cancer Therapy Could Influence Market Share Despite Incyte's Jakafi Comparison ↗

September 18, 2023

Friday, the FDA approved GSK plc's (NYSE: GSK) Ojjaara (momelotinib) for intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythemia vera and...

Via Benzinga

Incyte Hits Five-Year Low After GSK Snags Approval For A New Jakafi Rival ↗

September 18, 2023

Both companies now sell treatments for myelofibrosis, a rare bone marrow cancer.

Via Investor's Business Daily

One Year Into Kabir Nath's Leadership, Compass Pathways' (NASDAQ: CMPS) Phase 3 Trial For Innovative Treatment Resistant Depression Progressing ↗

September 18, 2023

Treatment-resistant depression, also referred to as TRD, is a subset of depression that poses significant challenges for clinicians, patients and those closest to patients. It is characterized by...

Via Benzinga

Pleasant Surprise For GSK: FDA Approves Bone Marrow Cancer Therapy Acquired Via Sierra Oncology Deal ↗

September 18, 2023

FDA has

Via Benzinga

Moderna's R&D Day Unveils Strategic Roadmap Beyond COVID Franchise: Goldman Sachs ↗

September 14, 2023

On Wednesday, Moderna Inc (NASDAQ: MRNA) conducted an R&D Day event outlining its strategic initiatives across four key areas - Respiratory Vaccines, Latent/Other Vaccines, Oncology Therapeutics,

Via Benzinga

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

38 39 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.